Please provide your email address to receive an email when new articles are posted on . Ultomiris is a C5 complement inhibitor for neuromyelitis optica spectrum disorder. Trial patients did not ...

Neuromyelitis optica is a rare chronic condition that causes eye pain and even vision loss. This disease happens when your own immune system attacks your nervous system. In this article, we look at ...

New research published in Science Translational Medicine suggests exposure to disease specific maternal autoantibody may affect blood brain barrier formation. MANHASSET, N.Y.--(BUSINESS ...

Neuromyelitis optica spectrum disorder (NMOSD)—an autoimmune disease of the optic nerve, spinal cord, or both, which can result in blindness or paralysis—may result in insulin resistance, a new study ...

(RTTNews) - The European Commission has approved Horizon Therapeutics plc's (HZNP) Uplizna or inebilizumab for the treatment of adults with Neuromyelitis Optica Spectrum Disorder. Uplizna is indicated ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. Dr ...

BARCELONA, Spain — Use of ravulizumab for long-term treatment of neuromyelitis optica spectrum disorder (NMOSD) offered sustained protection from relapse for at least 3 years, results from the ...

(RTTNews) - Roche (RHHBY) said Monday that the U.S. Food and Drug Administration has approved ENSPRYNG for Neuromyelitis Optica Spectrum Disorder or NMOSD. The First and only FDA-approved subcutaneous ...

"The key learning from this work is that timely treatment transitions may hold equatable benefit to the prescribed treatments themselves… the time between moving from one treatment to another was ...

– Enspryng lowered relapse severity in double-blind periods of SAkura Phase III studies – – Pooled data from SAkura open-label extension (OLE) studies support continued effect of Enspryng reducing ...